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Abstract: Antimony toxicity occurs either due to occupational exposure or during therapy. 
Occupational exposure may cause respiratory irritation, pneumoconiosis, antimony spots 
on the skin and gastrointestinal symptoms. In addition antimony trioxide is possibly 
carcinogenic to humans. Improvements in working conditions have remarkably decreased 
the incidence of antimony toxicity in the workplace. As a therapeutic, antimony has been 
mostly used for the treatment of leishmaniasis and schistosomiasis. The major toxic side-
effects of antimonials as a result of therapy are cardiotoxicity (~9% of patients) and 
pancreatitis, which is seen commonly in HIV and visceral leishmaniasis co-infections. 
Quality control of each batch of drugs produced and regular monitoring for toxicity is 
required when antimonials are used therapeutically. 
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1. Introduction 
Antimony (symbol Sb from the latin stibium) is a silvery white metal with atomic number 51, that is 
found in the earth’s crust. Its main applications are industrial. Elemental antimony can be used for 
producing semiconductors, infrared detectors and diodes. Because of its relative inflexibility, it is 
usually mixed into alloys for further application, e.g., manufacture of lead storage batteries, solder, 
sheet and pipe metal, bearings, castings and pewter, etc. Antimony oxide can be used in fire-retardant 
formulations for plastics, rubbers, textiles, paper and paints whereas antimony trisulfide is used in the 
production of explosives, pigments, antimony salts and ruby glass [1-3]. Antimony compounds have 
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been used as medicines since their introduction by the alchemist John of Rupescissa in the 14th 
century [4], mainly in the treatment of two parasitic diseases, leishmaniasis and schistosomiasis.  
Antimony and its compounds are naturally present in the Earth’s crust and are released into the 
environment by natural discharges such as windblown dust, volcanic eruptions, sea spray, forest fires, 
and biogenic sources. The concentration of antimony in air ranges from a nanogram per cubic meter 
(ng/m
3
) to about 170 ng/m
3
. The concentration of antimony that is found dissolved in rivers and lakes 
is usually less than 5 parts of antimony in 1 billion parts of water (ppb) and it is found attached to 
particles of dirt. Antimony occurs predominantly in the pentavalent state in aerobic fresh water and sea 
water and the trivalent state is more common under anaerobic conditions as well as a results of 
anthropogenic activities. A U.S. geological survey showed that soil concentrations range from less 
than 1 to 8.8 ppm, with a mean of 0.48 ppm [5]. The average intake of antimony from food and water 
was estimated to be roughly 5 μg/day in a study [6]. These data show that the general population is 
exposed to low levels of antimony. Toxicity may arise during occupational exposure, domestic use or 
when it is used as a therapy. This review discusses antimony toxicity arising from occupational 
exposure and when it is used as a therapy. 
2. Results and Discussion  
2.1. Antimony as an Occupational Hazard 
Occupational exposure to antimony occurs mainly in workers involved in industries producing 
antimony and antimony trioxide, metal mining, smelting and refining, coal-fired power plants, refuse 
incineration, or those working in indoor firing ranges. Most of the data of antimony toxicity comes 
from the time when primitive work conditions prevailed and there was no adequate protection for the 
workers. Another problem in assessing its toxicity industrially is that arsenic and lead are often found 
with it, and other toxic materials may also be produced in the course of the process, and separation of 
exposures may be difficult or impossible. 
2.1.1. Inhalational Exposure 
Health effects have been observed following inhalational exposure to several antimony compounds 
e.g., antimony trioxide, stibine (antimony hydride), antimony trisulfide, antimony pentoxide, antimony 
trichloride, antimony pentasulfide, metallic antimony, etc. The absorption of antimony from the 
respiratory tract is a function of particle size. Aerosols containing small particles composed of 
antimony compounds with low water solubility (e.g., particles of antimony oxides) are retained in the 
lungs for a longer period of time than those containing larger particles with high water solubility  
(e.g., particles of antimony tartrate) [7,8].  
2.1.1.1. Respiratory Effects 
Chronic exposure to antimony trioxide and/or pentoxide dust (8.87 mg antimony/m
3 
or greater) was 
seen to cause pneumoconiosis, however, these workers were also exposed to a variety of other 
compounds like arsenic oxide, iron oxide, hydrogen sulfide, and sodium hydroxide [9,10]. Antimony 
pneumoconiosis was also described by Karajovic in a population of antimony miners and smelters in 
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Yugoslavia based on diffuse x-ray opacities but this was also confounded by simultaneous  
silicosis [11]. Other respiratory effects reported in workers include chronic bronchitis, chronic 
emphysema, inactive tuberculosis, pleural adhesions, and respiratory irritation (characterized by 
chronic coughing, wheezing and upper airway inflammation) [10]. Similar findings were seen in 
animal studies [12].  
2.1.1.2. Cardiovascular Effects 
Cardiovascular effects in humans are supported by the finding of cardiac effects following 
parenteral administration of antimony to humans. Increased blood pressure and altered ECG 
(electrocardiography) readings mostly of the T-waves were observed in workers exposed to 2.15 mg 
antimony/m
3 
as antimony trisulfide for 8 months to 2 years; however these workers had also been 
exposed to phenol formaldehyde resin. Inhalation exposure to antimony trisulfide dust was also seen to 
result in degenerative changes in the myocardium and related ECG abnormalities in variety of animal 
species [13]. Nevertheless, evidence of heart disease from industrial exposure to antimony is not  
very strong. 
2.1.1.3. Gastrointestinal Effects 
Repeated prolonged exposure to airborne antimony trichloride [14], antimony trisulfide [13] or 
antimony oxide [15] was seen to cause abdominal pain, diarrhea, vomiting, and ulcers. A causal 
relationship to antimony exposure has not been definitely established because workers were exposed to 
a variety of other agents in addition to antimony that might cause or contribute to gastrointestinal 
effects (e.g., hydrogen chloride, sodium hydroxide). 
2.1.1.4. Dermal effects 
Airborne antimony has effects in skin described as “antimony spots” which are pustules and 
eruptions in the trunk and limbs near sweat and sebaceous glands. This dermatitis is more commonly 
seen in association with hot weather and in workers exposed to high temperatures [10,16,17]. 
Transferring the worker to a cooler environment often resulted in the rash clearing up within 3–14 days. 
2.1.1.5. Reproductive Effects 
Two thirds of rats exposed to 209 mg antimony/m
3
 as antimony trioxide for 63 days failed to 
conceive. An increased incidence of spontaneous abortions and disturbances in menstruation, were 
reported in women working at an antimony metallurgical plant as compared to a control group. The 
women were exposed to a mixture of antimony trioxide, antimony pentasulfide, and metallic  
antimony [18]. 
2.1.1.6. Carcinogenicity 
There is inadequate evidence for carcinogenicity of antimony trioxide and trisulphide in humans but 
antimony trioxide and antimony trisulfide have been seen to cause lung tumours in rats. Antimony 
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trioxide is classified as possibly carcinogenic to humans (Group 2B) by the International Agency for 
Research on Cancer [3].  
2.1.1.7. Genotoxicity 
The results of in vitro genotoxicity studies have shown positive results for chromosome breakage in 
human leukocytes [19]. In a study to assess genotoxic risk and oxidative damage in workers exposed 
to antimony trioxide, there was no difference in sister chromatid exchange and micronuclei between 
those exposed and controls however, increased oxidative damage to DNA was observed in the exposed 
group [20]. In a recent study, antimony showed genotoxicity in both bacterial mutation tests and 
chromosomal aberration tests in cultured mammalian cells [21]. Due to lack of in vivo studies 
genotoxicity in humans cannot be determined at this time. 
2.1.2. Oral Exposure 
Historically, antimony has been known for its emetic properties. Amounts as low as 0.529 mg/kg 
can result in vomiting. Oral exposure to antimony predominantly affects the gastrointestinal system. 
Seventy people became acutely ill after drinking lemonade containing 0.013% antimony. The 
lemonade had been prepared and left overnight in buckets coated with enamel containing 2.88% 
antimony trioxide. Fifty-six people were taken to the hospital with burning stomach pains, colic, 
nausea and vomiting. Most recovered within 3 hours, but in some cases recovery was not complete for 
several days [22]. It is estimated that a person consuming 300 mL of lemonade would have received a 
dose of approximately 36 mg antimony, or approximately 0.5 mg/kg for a 70-kg adult. No other 
toxicity has been recorded in humans for oral exposure to antimony.  
2.1.3. Other Exposure from Antimony Compounds 
Antimony was implicated in the cause of cot deaths, or Sudden Infant Death Syndrome (SIDS) by 
Richardson in 1990 [23]. It was claimed that antimony compounds used in fireproofing cot furnishings 
amongst other additives was primarily responsible for SIDS due to the action of a fungus 
(Scopulariopsis brevicaulis) growing on polyvinyl chloride cot mattress covers. In vitro experiments 
appeared to demonstrate the release of stibine and phosphine, hydrides of antimony oxide fire retardant 
and phosphorus plasticisers from polyvinyl chloride mattress covers which had been treated with these 
substances and it was claimed that they had caused deaths from their toxicity. However, urine 
antimony concentration of antimony in infants dying from SIDS were similar to values found in 
control infants and healthy infants [24]. This causal role of antimony in SIDS was ultimately refuted 
due to lack of evidence. 
Recently the National Institute for Occupational Safety and Health investigated a possible outbreak 
of antimony toxicity wherein 30 firefighters reported elevated antimony levels on hair analyses as 
some fire fighter station uniforms contain the flame-retardant antimony trioxide. However, no 
differences in urine antimony levels between departments wearing and not wearing this uniform were 
detected. It was hence concluded that wearing antimony-containing uniforms does not pose a risk for 
antimony toxicity [25]. The CDC stated in their report that only validated methods should be used for 
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the determination of antimony toxicity. Urine testing is the most accurate, reliable, and valid test 
method for measuring antimony levels in the body. CDC has established ranges for urine levels of 
antimony in the U.S. population: 0.120–0.364 micrograms/gram creatinine. Hair testing is not a 
validated method for heavy metals testing (which includes antimony), and is not recommended [26]. 
2.1.4. Prevention of Exposure to Antimony 
To safeguard the general public in USA, the Environmental Protection Agency (EPA) allows  
0.006 parts of antimony per million parts of drinking water [27]. In the guidelines for Drinking-water 
Quality, WHO established a tolerable daily intake (TDI) of 6 μg/kg bodyweight/day for antimony [28].  
The EPA requires that discharges or spills into the environment of 5,000 pounds or more of 
antimony be reported. The Occupational Safety and Health Administration (OSHA) has set an 
occupational exposure limit of 0.5 milligrams of antimony per cubic meter of air (0.5 mg/m³) for an  
8-hour workday, 40-hour workweek [5].  
2.2. Antimony in Therapeutics 
Antimony had a reputation of being a universal panacea of all kinds of diseases in the middle ages. 
In 1631, the German alchemist Adrian Von Mynsicht successfully described potassium antimony 
tartrate [29]. Since the last century antimonials have been used for the treatment of two parasitic 
diseases schistosomiasis and leishmaniasis. 
2.2.1. Schistosomiasis  
A number of antimony compounds have been used for the treatment of schistosomiasis e.g., sodium 
antimony tartrate, sodium antimony dimercaptosuccinate (stibocaptate, Astiban) sodium antimonyl 
gluconate, etc. [30,31]. In a comparative trial of three antimonials used in schistosomiasis, 78% 
patients had gastrointestinal symptoms e.g., vomiting, anorexia. Arthralgia was common in all the 
three groups, but severity of the symptoms were more in patients taking antimony sodium tartrate 
(AST) and sodium antimonyl gluconate (TSAG). Complete flattening or frank inversion of T waves in 
ECG was seen in 68%, 67% and 42% of TSAG, AST and TWSb (antimony dimercaptosuccinate) 
respectively. Although substernal pain was common only three cases on i.v. sodium antimony tartrate 
had an acute vascular collapse. Cough was a common symptom however pneumonia occurred in two 
patients and hepatotoxicity was observed in 1.9% patients [31]. With the advent of the more 
efficacious and less toxic alternative praziquantel, the trivalent antimonials were phased out from the 
treatment of schistosomiasis in the 1970s. 
2.2.2. Leishmaniasis 
In 1912, Vianna successfully used tartar emetic to cure cutaneous leishmaniasis for the first  
time [32]. In 1915 it was used for visceral leishmaniasis for the first time. Tartar emetic, although 
extremely effective in the treatment of leishmaniasis, was abandoned due to its toxicity. Injections led 
to severe vomiting and retching, apart from that pneumonia, joint pain, lung, kidney and bowel 
complication was also reported [33]. In 1923 the first pentavalent antimony compound urea stibamine 
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was discovered which had much less toxicity than its trivalent predecessor. Later it was replaced by 
sodium stibogluconate which to date remains the drug of choice for the treatment of visceral 
leishmaniasis worldwide, except in North Bihar where a high level of antimony resistance exists. 
Treatment with sodium antimony gluconate at the therapeutic dose may result in minor side effects 
such as arthralgia, myalgia, transient elevation of hepatocellular enzyme levels, and minor ECG  
changes [34,35]. A decrease in the height of T waves and T-wave inversion is seen in about 50% of 
patients [35]. Although serious cardiotoxicity is uncommon, occurring in less than 9% cases, death 
may result in these patients [34,36-38]. Features of dangerous cardiotoxicity include a concave ST 
segment and prolongation of the corrected QT interval (QTc), which is measured by dividing the QT 
interval by the square root of the preceding interval between the preceding two QRS complexes (RR 
interval) [39]. Normal QTc values are less than 0.37 s and 0.44 s for males and females, respectively, 
while an increase of 0.03 s or an absolute value of greater than 0.50 s are considered ominous [34,35]. 
In a cluster of cases with cardiotoxicity due to sodium antimony gluconate, the first dangerous sign 
of cardiotoxicity was prolonged QTc, followed by multiple ventricular ectopics, then ventricular 
tachycardia, torsade de pointes, ventricular fibrillation, and potentially death. In this series 
cardiotoxicity occurred at a much lower cumulative dose than previously reported and was associated 
with higher osmolarity of the batch of drugs. Elevated osmolarity reflects an increased concentration 
of particles, and thus reflect both the concentration of the drug and its state of aggregation. However, 
in this study implicated lot had comparable antimony contents as the effective lot, implying some other 
cause for the increase in their osmolarity. Incorrect formulation e.g., incorrect antimony to gluconate 
ratio and the presence of trivalent antimony in a preparation could also result in increased osmolarity, 
This study suggests that higher than expected osmolarity may serve as a nonspecific indicator of a 
problem in formulation [40]. Another outbreak of fatal cardiotoxicity occurred in Nepal amongst 
visceral leishmaniasis patients treated with a recently introduced batch of generic sodium 
stibogluconate. Eight (36%) of 23 patients treated with this batch died, and  five deaths (23%) were 
attributed to the cardiotoxicity of the drug [41]. 
The exact mechanism for cardiotoxicity is not known, but antimonials prolong the action potential 
of guinea pig ventricular myocytes at therapeutically relevant concentrations for the treatment of 
leishmaniasis via an increase in cardiac calcium currents. In the heart, calcium currents regulate the 
plateau phase of the cardiac action potential and increased amplitudes produce a delay in cardiac 
repolarization, which may explain the propensity of patients treated with antimonial compounds to 
develop QT prolongation and life-threatening arrhythmias [42]. It is now generally accepted that all 
pentavalent antimonials are prodrugs that require biological reduction to the trivalent form [Sb(III)] for 
antileishmanial activity. The site (amastigote or macrophage) and mechanism of reduction (enzymatic 
or nonenzymatic) remain controversial [43]. Although the exact molecular mechanism(s) underlying 
the increase in calcium currents observed with trivalent antimony is not known, it is postulated that 
high affinity for sulfhydryl groups may affect calcium channels by oxidizing cysteine residues located 
either directly on the channel protein or on a closely associated protein [44]. 
Pancreatitis is another adverse effect of pentavalent antimonials. Incidence of all adverse events and 
especially of pancreatitis is quite high in HIV and VL coinfection. In a study of 25 HIV-VL coinfected 
patients, adverse effects were observed in 56%. In seven (28%), treatment with meglumine 
antimoniate (MA) was discontinued permanently due to serious adverse effects that included acute 
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pancreatitis (5), acute renal failure (1), and leukopenia (1). Three (12%) patients died during therapy 
due to severe acute pancreatitis attributable to MA. Patients who developed acute pancreatitis were not 
alcohol drinkers, their triglyceride levels were not elevated and the biliary tree was normal on 
abdominal ultrasound examination [45]. The reasons behind increased pancreatitis in these patients 
could be multiple. Amount of antimony has been seen to vary with different batches which could lead 
to use of higher doses of Sb
V
 than intended [46]. Subclinical pancreatitis frequently occurs in patients 
with AIDS which could predispose them to pancreatic disease [47,48]. Elevation of pancreatic and 
liver enzymes were also observed in a study of new world cutaneous leishmaniasis in which 
pentavaalent antimonials were given at the dose of 20 mg/kg/day for 20 days. The most prominent 
complaints, myalgia and abdominal
 
pain, were reported by 29–56% and 4–25% of the patients, 
respectively. Another 46–69% had mild-to-moderate elevations and 2–19% had grade 3 elevations of 
pancreatic enzymes, whereas, 44–75% had mild-to-moderate elevations and 4–12% had grade 3 
elevations of liver enzymes [49].  
In Brazil higher frequency of skin reactions was observed in some patients of cutaneous 
leishmaniasis treated with meglumine antimoniate. This lot of drugs had lower pH and osmolarity and 
higher concentrations of total and trivalent antimony, lead, cadmium and arsenic and the skin reaction 
was attributed to the heavy metal contamination [50]. 
3. Conclusions 
With dramatic improvements in working conditions in antimony processing and stringent guidelines 
antimony has largely ceased to be a common occupational health hazard, however, constant vigilance 
is required for emerging toxicity. 
As for its use as a therapeutic agent, continuous quality control of each batch of drugs produced 
should be done to ensure safety. The simple technique of measuring of osmolarity may help identify 
inappropriately manufactured drugs. Regular monitoring for toxicity needs to be done. Use of alternate 
less toxic drugs for the treatment of leishmaniasis especially in HIV co-infected patients could be 
another strategy. Availability of drugs like miltefosine, paramomycin and liposomal Amphotericin B 
(L-AmB) makes this a viable option. Moreover, a preferential pricing agreement with WHO 
(agreement between Gilead and WHO of 14 March 2007) has recently reduced the price of L-AmB 
(AmBisome®) for endemic regions to $20 per 50-mg vial [51]. This preferential pricing further opens 
the prospect of either single dose treatment or short course combination regimens. Combining multiple 
drugs not only reduces toxicity of individual drugs but also reduces drug pressure, decreases duration 
of treatment leading to better compliance, decreased hospital stay and ultimately cost of therapy. 
Paromomycin was one of the first drug to be used in combination with pentavalent antimony 
compounds in the 1990s in Kenya, India and Sudan [52-54]. This combination is currently in use in 
Sudan [55]. Well conducted trials of combination therapy are the need of the hour to increase efficacy, 
decrease toxicity and prevent resistance.  
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